Artiva biotherapeutics, inc.ARTV.US Overview
ARTV Overall Performance
ARTV AI Analysis & Strategy
ARTV Recent Performance
5.21%
Artiva biotherapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ARTV PowerScanner
ARTV Key Information
ARTV Valuation Metrics
ARTV Earnings Table
ARTV Profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.